{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:17:28Z","timestamp":1779315448828,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report for the first time the effect of psilocybin in a PD patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A non-depressed 43-year-old female with a 2-year history of PD presented with difficulty adjusting to PD, anxious ruminations and pessimism. The patient declined an increase in dopaminergic medication or the introduction of an anxiolytic. Therapeutic patient education was not beneficial. The patient received four sessions of high-dose PAP within one year. Neurological and psychiatric assessments were performed before and at one year follow-up using qualitative interviews and quantitative assessment of motor status, dispositional optimism, depression, anxiety, apathy, and well-being.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PAP was well tolerated. It significantly improved the patient's overall pessimistic outlook on her future and decreased her anxious ruminations and worries about potential handicap due to PD. Her general well-being improved, as well as all psychometric scores except for the apathy scale. Motor status remained unchanged. Better acceptance of PD allowed her to accept pharmacological treatment adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PAP could be a safe and useful treatment for PD patients with dispositional pessimism and difficulties accepting their disease by promoting profound decentration from habitual thoughts and emotions, improving mood and PD acceptance. Randomized, controlled studies are needed to confirm this result.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x241312604","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:07:49Z","timestamp":1738541269000},"page":"440-444","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-6829","authenticated-orcid":false,"given":"Vanessa","family":"Fleury","sequence":"first","affiliation":[{"name":"Department of Neurology, Geneva University Hospital, Geneva, Switzerland"},{"name":"Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Tomkova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-5827","authenticated-orcid":false,"given":"Sabina","family":"Catalano Chiuv\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-0243","authenticated-orcid":false,"given":"Louise","family":"Penzenstadler","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Geneva, Geneva, Switzerland"},{"name":"Department of Psychiatry, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-020-0367-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.05.051"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13549"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105926"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18063308"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18168653"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.767215"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1420601"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512513"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amp.2024.05.014"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22577"},{"key":"e_1_3_4_19_2","volume-title":"Manual for the State-Trait Anxiety Inventory STAI (Form Y) (\u201cSelf-Evaluation Questionnaire)","author":"Spielberger CD","year":"1983","unstructured":"Spielberger CD. Manual for the State-Trait Anxiety Inventory STAI (Form Y) (\u201cSelf-Evaluation Questionnaire). Palo Alto, CA ed.: Consulting Psychologists Press, Inc., 1983."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6703_13"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12607"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-3514.67.6.1063"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2014.0297"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_4_28_2","first-page":"39","article-title":"The impact of psilocybin on patients experiencing psychiatric symptoms: a systematic review of randomized clinical trials","volume":"20","author":"IsHak WW","year":"2023","unstructured":"IsHak WW, Garcia P, Pearl R, et al. The impact of psilocybin on patients experiencing psychiatric symptoms: a systematic review of randomized clinical trials. Innov Clin Neurosci 2023; 20: 39\u201348.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_459"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117731279"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2018.1474185"},{"key":"e_1_3_4_35_2","volume-title":"Therapy Adherence Rating Scale. Interpersonal process in Cognitive Therapy","author":"Safran JD","year":"1990","unstructured":"Safran JD, Segal ZV. Therapy Adherence Rating Scale. Interpersonal process in Cognitive Therapy. New York: Basic Books, 1990."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01706-y"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1199642"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13741"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817709585"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32649-7"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07624-5"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.01.005"},{"key":"e_1_3_4_45_2","first-page":"113","article-title":"Dispositional optimism, depression, disability and quality of life in Parkinson's disease","volume":"29","author":"Gison A","year":"2014","unstructured":"Gison A, Dall'Armi V, Donati V, et al. Dispositional optimism, depression, disability and quality of life in Parkinson's disease. Funct Neurol 2014; 29: 113\u2013119.","journal-title":"Funct Neurol"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012"},{"key":"e_1_3_4_47_2","unstructured":"United Nations Office on Drugs and Crime. . World Drug Report 2024. https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2024.html (2024)."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X241312604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X241312604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X241312604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:51:09Z","timestamp":1777589469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X241312604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/1877718X241312604"],"URL":"https:\/\/doi.org\/10.1177\/1877718x241312604","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,2]]}}}